サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1292715

ライブバイオセラピー製品およびマイクロバイオームCDMOの世界市場規模、シェア、産業動向分析レポート：用途別（C.difficile、クローンズ病、IBS、糖尿病、その他）、地域別展望と予測、2023年～2029年

Global Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Industry Trends Analysis Report By Application (C.difficile, Crohns Disease, IBS, Diabetes, and Others), By Regional Outlook and Forecast, 2023 - 2029
出版日: | 発行: KBV Research | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ライブバイオセラピー製品およびマイクロバイオームCDMOの世界市場規模、シェア、産業動向分析レポート：用途別（C.difficile、クローンズ病、IBS、糖尿病、その他）、地域別展望と予測、2023年～2029年
出版日: 2023年05月31日
発行: KBV Research
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ライブバイオセラピー製品およびマイクロバイオームCDMO市場規模は、2029年までに1億5,910万米ドルに達し、予測期間中にCAGR42.5%の市場成長率で上昇すると予測されています。

世界の製品需要の増加の影響は、新規の薬用レメディーの創出に火をつける重要な市場現象です。製品需要の増加、マイクロバイオームとLBP治療の大きな盛り上がりの結果、市場は予測期間を通じて成長見通しが立つと予想されます。現在、自閉症に対して日常的に使用される決定的な治療法は存在しません。使用されている治療法の中には、感覚統合、認知教育、理学療法があります。新しい調査では、腸内細菌叢を変化させることで自閉症児を治療することが有効である可能性が示唆されています。

しかし、生きた微生物の増殖は、その生産段階でも、ライフサイクルの残りの段階でも、コントロールすることは困難です。LBPの製造には、原料の品質（医薬品グレード、理想的には動物由来物質を含まない）と製造工程（環境条件、製造施設、使用機器を含む）が重要であることが一般的に知られています。さらに、衛生管理に関する従業員の教育、管理手順と品質モニタリングも最も重要です。したがって、これらの要素はすべて、予測期間を通じて市場の成長を阻害する可能性があります。

アプリケーションの展望

アプリケーションに基づき、ライブバイオセラピー製品およびマイクロバイオームCDMO市場は、C.difficile、クローン病、IBS、糖尿病、およびその他に分類されます。2022年のライブバイオセラピー製品およびマイクロバイオームCDMO市場では、C.difficileセグメントが最も高い収益シェアを獲得しました。特に、現在抗生物質を使用している患者では、ヒトの腸内細菌叢に存在するC.difficileという細菌が深刻な下痢や大腸炎を引き起こすことがあります。そのため、ライブバイオセラピー製品は、腸内細菌叢を含むさまざまな病気を治す可能性があるとして、近年、注目が高まっています。

地域別の展望

地域別に見ると、ライブバイオセラピー製品およびマイクロバイオームCDMOの市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2022年のライブバイオセラピー製品およびマイクロバイオームCDMO市場において最大の収益シェアを記録しました。この上昇は、同地域における重要な企業の存在と研究開発活動への投資の高まりが主な要因となっています。しかし、北米の市場拡大は、C.diff、クローン病、IBSなどのさまざまな病気に対する効果的な治療法に対する需要の高まりにも影響を受けています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 世界のライブバイオセラピー製品およびマイクロバイオームCDMO市場：用途別

  • 世界のCdifficile市場：地域別
  • 世界のクローン病市場：地域別
  • 世界のIBS市場：地域別
  • 世界の糖尿病市場：地域別
  • 世界のその他の市場：地域別

第4章 世界のライブバイオセラピー製品およびマイクロバイオームCDMO市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第5章 企業プロファイル

  • Arranta Bio Holdings, LLC（Recipharm AB）（EQT AB）
  • Cerbios-Pharma SA
  • Biose Industrie
  • List Biological Laboratories, Inc
  • AcuraBio Pty Ltd（Ampersand Capital Partners）
  • Wacker Chemie AG（Dr Alexander Wacker Familiengesellschaft mbH）
  • Quay Pharmaceuticals Ltd（SGS SA.）
  • BiomX, Inc
  • Lonza Group AG
  • 4D Pharma Plc
図表

LIST OF TABLES

  • TABLE 1 Global Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 2 Global Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 3 Global Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 4 Global Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 5 Global C.difficile Market by Region, 2019 - 2022, USD Thousands
  • TABLE 6 Global C.difficile Market by Region, 2023 - 2029, USD Thousands
  • TABLE 7 Global Crohns Disease Market by Region, 2019 - 2022, USD Thousands
  • TABLE 8 Global Crohns Disease Market by Region, 2023 - 2029, USD Thousands
  • TABLE 9 Global IBS Market by Region, 2019 - 2022, USD Thousands
  • TABLE 10 Global IBS Market by Region, 2023 - 2029, USD Thousands
  • TABLE 11 Global Diabetes Market by Region, 2019 - 2022, USD Thousands
  • TABLE 12 Global Diabetes Market by Region, 2023 - 2029, USD Thousands
  • TABLE 13 Global Others Market by Region, 2019 - 2022, USD Thousands
  • TABLE 14 Global Others Market by Region, 2023 - 2029, USD Thousands
  • TABLE 15 Global Live Biotherapeutic Products And Microbiome CDMO Market by Region, 2019 - 2022, USD Thousands
  • TABLE 16 Global Live Biotherapeutic Products And Microbiome CDMO Market by Region, 2023 - 2029, USD Thousands
  • TABLE 17 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 18 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 19 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 20 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 21 North America C.difficile Market by Country, 2019 - 2022, USD Thousands
  • TABLE 22 North America C.difficile Market by Country, 2023 - 2029, USD Thousands
  • TABLE 23 North America Crohns Disease Market by Country, 2019 - 2022, USD Thousands
  • TABLE 24 North America Crohns Disease Market by Country, 2023 - 2029, USD Thousands
  • TABLE 25 North America IBS Market by Country, 2019 - 2022, USD Thousands
  • TABLE 26 North America IBS Market by Country, 2023 - 2029, USD Thousands
  • TABLE 27 North America Diabetes Market by Country, 2019 - 2022, USD Thousands
  • TABLE 28 North America Diabetes Market by Country, 2023 - 2029, USD Thousands
  • TABLE 29 North America Others Market by Country, 2019 - 2022, USD Thousands
  • TABLE 30 North America Others Market by Country, 2023 - 2029, USD Thousands
  • TABLE 31 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
  • TABLE 32 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
  • TABLE 33 US Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 34 US Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 35 US Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 36 US Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 37 Canada Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 38 Canada Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 39 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 40 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 41 Mexico Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 42 Mexico Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 43 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 44 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 45 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 46 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 47 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 48 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 49 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 50 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 51 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 52 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 53 Europe C.difficile Market by Country, 2019 - 2022, USD Thousands
  • TABLE 54 Europe C.difficile Market by Country, 2023 - 2029, USD Thousands
  • TABLE 55 Europe Crohns Disease Market by Country, 2019 - 2022, USD Thousands
  • TABLE 56 Europe Crohns Disease Market by Country, 2023 - 2029, USD Thousands
  • TABLE 57 Europe IBS Market by Country, 2019 - 2022, USD Thousands
  • TABLE 58 Europe IBS Market by Country, 2023 - 2029, USD Thousands
  • TABLE 59 Europe Diabetes Market by Country, 2019 - 2022, USD Thousands
  • TABLE 60 Europe Diabetes Market by Country, 2023 - 2029, USD Thousands
  • TABLE 61 Europe Others Market by Country, 2019 - 2022, USD Thousands
  • TABLE 62 Europe Others Market by Country, 2023 - 2029, USD Thousands
  • TABLE 63 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
  • TABLE 64 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
  • TABLE 65 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 66 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 67 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 68 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 69 UK Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 70 UK Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 71 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 72 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 73 France Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 74 France Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 75 France Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 76 France Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 77 Russia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 78 Russia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 79 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 80 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 81 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 82 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 83 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 84 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 85 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 86 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 87 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 88 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 89 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 90 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 91 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 92 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 93 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 94 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 95 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 96 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 97 Asia Pacific C.difficile Market by Country, 2019 - 2022, USD Thousands
  • TABLE 98 Asia Pacific C.difficile Market by Country, 2023 - 2029, USD Thousands
  • TABLE 99 Asia Pacific Crohns Disease Market by Country, 2019 - 2022, USD Thousands
  • TABLE 100 Asia Pacific Crohns Disease Market by Country, 2023 - 2029, USD Thousands
  • TABLE 101 Asia Pacific IBS Market by Country, 2019 - 2022, USD Thousands
  • TABLE 102 Asia Pacific IBS Market by Country, 2023 - 2029, USD Thousands
  • TABLE 103 Asia Pacific Diabetes Market by Country, 2019 - 2022, USD Thousands
  • TABLE 104 Asia Pacific Diabetes Market by Country, 2023 - 2029, USD Thousands
  • TABLE 105 Asia Pacific Others Market by Country, 2019 - 2022, USD Thousands
  • TABLE 106 Asia Pacific Others Market by Country, 2023 - 2029, USD Thousands
  • TABLE 107 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
  • TABLE 108 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
  • TABLE 109 China Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 110 China Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 111 China Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 112 China Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 113 Japan Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 114 Japan Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 115 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 116 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 117 India Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 118 India Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 119 India Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 120 India Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 121 South Korea Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 122 South Korea Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 123 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 124 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 125 Singapore Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 126 Singapore Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 127 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 128 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 129 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 130 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 131 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 132 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 133 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 134 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 135 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 136 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 137 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 138 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 139 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 140 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 141 LAMEA C.difficile Market by Country, 2019 - 2022, USD Thousands
  • TABLE 142 LAMEA C.difficile Market by Country, 2023 - 2029, USD Thousands
  • TABLE 143 LAMEA Crohns Disease Market by Country, 2019 - 2022, USD Thousands
  • TABLE 144 LAMEA Crohns Disease Market by Country, 2023 - 2029, USD Thousands
  • TABLE 145 LAMEA IBS Market by Country, 2019 - 2022, USD Thousands
  • TABLE 146 LAMEA IBS Market by Country, 2023 - 2029, USD Thousands
  • TABLE 147 LAMEA Diabetes Market by Country, 2019 - 2022, USD Thousands
  • TABLE 148 LAMEA Diabetes Market by Country, 2023 - 2029, USD Thousands
  • TABLE 149 LAMEA Others Market by Country, 2019 - 2022, USD Thousands
  • TABLE 150 LAMEA Others Market by Country, 2023 - 2029, USD Thousands
  • TABLE 151 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
  • TABLE 152 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
  • TABLE 153 Brazil Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 154 Brazil Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 155 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 156 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 157 Argentina Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 158 Argentina Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 159 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 160 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 161 UAE Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 162 UAE Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 163 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 164 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 165 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 166 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 167 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 168 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 169 South Africa Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 170 South Africa Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 171 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 172 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 173 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 174 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 175 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 176 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 177 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
  • TABLE 178 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
  • TABLE 179 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
  • TABLE 180 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
  • TABLE 181 Key Information - Arranta Bio Holdings, LLC
  • TABLE 182 Key Information - Cerbios-Pharma SA
  • TABLE 183 Key Information - Biose Industrie
  • TABLE 184 Key Information - List Biological Laboratories, Inc.
  • TABLE 185 Key Information - AcuraBio Pty Ltd
  • TABLE 186 Key Information - Wacker Chemie AG
  • TABLE 187 Key Information - Quay Pharmaceuticals Ltd
  • TABLE 188 Key Information - BiomX, Inc.
  • TABLE 189 Key Information - Lonza Group AG
  • TABLE 190 Key Information - 4D Pharma Plc

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2022
  • FIG 3 Global Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2029
  • FIG 4 Global Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2029, USD Thousands
  • FIG 5 Global Live Biotherapeutic Products And Microbiome CDMO Market share by Region, 2022
  • FIG 6 Global Live Biotherapeutic Products And Microbiome CDMO Market share by Region, 2029
  • FIG 7 Global Live Biotherapeutic Products And Microbiome CDMO Market by Region, 2019 - 2029, USD Thousands
目次

The Global Live Biotherapeutic Products And Microbiome CDMO Market size is expected to reach $159.1 million by 2029, rising at a market growth of 42.5% CAGR during the forecast period.

Diabetes is one of the major applications of live biotherapeutic products and microbiome CDMO market and captured more than 35% share in the market during 2022 as it is recognized as one of the most important unaddressed worldwide health problems. It poses a significant risk for several prevalent, occasionally fatal conditions like hypertension, coronary heart disease, stroke, kidney failure, and retinopathy. According to WHO, approximately 2 million people died in 2019 from diabetes-related renal damage. A total of 1.5 million deaths were directly related to diabetes in 2019, and 48% of these deaths occurred in those under the age of 70. Diabetes contributed to an additional 460 000 renal disease fatalities, and elevated blood glucose is responsible for almost 20% of cardiovascular mortality. Some of the factors impacting the market are increasing efforts to create novel treatments for different ailments, recent development in live biotherapeutic products that can modulate neurological diseases associated with the gut-brain axis, and lack of standards and infrastructure for developing LBPs.

During the COVID-19 outbreak, people were more concerned about contracting bacterial and viral diseases. The COVID-19 pandemic necessitated a significant reallocation of resources to be focused on the diagnostic, treatment, as well as vaccination efforts. Because of this, resources were diverted from the development of live biotherapeutic products and used in other healthcare fields instead. In addition, during the pandemic, there was a significant drop in consumer demand for LBPs, which had a detrimental impact on market growth.

The impact of increasing product demand globally is a crucial market phenomenon that has sparked the creation of novel medicinal remedies. The market is expected to see growth prospects throughout the projection period as a result of rising product demand and a major uptick in the microbiome and LBP therapies. There is currently no definitive treatment used routinely for autism. Among the treatments used are sensory integration, cognitive education, and physical therapy. New research suggests that treating autistic children by changing their gut microbiota may be effective.

However, it is difficult to exert any degree of control on the expansion of live microbes, either at the level of their production or during the remaining stages of their lifecycles. It is generally known that the quality of the raw materials (pharmaceutical grade and ideally free of substances derived from animals) and the manufacturing process (which includes the environmental conditions, production facility and equipment used) are important for LBP production. Additionally, the education of employees in hygiene & sanitation and the control procedures and quality monitoring are of utmost importance as well. Hence, all these elements may hamper the market's growth throughout the forecast period.

Application Outlook

Based on application, the live biotherapeutic products and microbiome CDMO market is characterized into C.difficile, Crohn's disease, IBS, diabetes, and others. The C.difficile segment garnered the highest revenue share in the live biotherapeutic products and microbiome CDMO market in 2022. In particular, in patients who are currently using antibiotics, the bacterium C. difficile, which is present in the human gut microbiome, can cause serious diarrhea and colitis. As a result, live biotherapeutic products have attracted increasing attention in recent years due to their potential to cure a variety of illnesses, including those involving the gut microbiome.

Regional Outlook

Region wise, the live biotherapeutic products and microbiome CDMO market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the live biotherapeutic products and microbiome CDMO market in 2022. This rise is mostly attributable to the presence of important firms and rising investments in R&D activities in the region. However, the expansion of the market in North America has also been influenced by the rising demand for effective therapies for a variety of illnesses such as C. diff, Crohn's disease, and IBS.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.

Scope of the Study

Market Segments covered in the Report:

By Application

  • C.difficile
  • Crohns Disease
  • IBS
  • Diabetes
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
  • Cerbios-Pharma SA
  • Biose Industrie
  • List Biological Laboratories, Inc.
  • AcuraBio Pty Ltd (Ampersand Capital Partners)
  • Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
  • Quay Pharmaceuticals Ltd (SGS S.A.)
  • BiomX, Inc.
  • Lonza Group AG
  • 4D Pharma Plc

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Live Biotherapeutic Products And Microbiome CDMO Market, by Application
    • 1.4.2 Global Live Biotherapeutic Products And Microbiome CDMO Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Live Biotherapeutic Products And Microbiome CDMO Market by Application

  • 3.1 Global C.difficile Market by Region
  • 3.2 Global Crohns Disease Market by Region
  • 3.3 Global IBS Market by Region
  • 3.4 Global Diabetes Market by Region
  • 3.5 Global Others Market by Region

Chapter 4. Global Live Biotherapeutic Products And Microbiome CDMO Market by Region

  • 4.1 North America Live Biotherapeutic Products And Microbiome CDMO Market
    • 4.1.1 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.1.1.1 North America C.difficile Market by Country
      • 4.1.1.2 North America Crohns Disease Market by Country
      • 4.1.1.3 North America IBS Market by Country
      • 4.1.1.4 North America Diabetes Market by Country
      • 4.1.1.5 North America Others Market by Country
    • 4.1.2 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country
      • 4.1.2.1 US Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.1.2.1.1 US Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.1.2.2 Canada Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.1.2.2.1 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.1.2.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.1.2.3.1 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.1.2.4 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.1.2.4.1 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
  • 4.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market
    • 4.2.1 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.1.1 Europe C.difficile Market by Country
      • 4.2.1.2 Europe Crohns Disease Market by Country
      • 4.2.1.3 Europe IBS Market by Country
      • 4.2.1.4 Europe Diabetes Market by Country
      • 4.2.1.5 Europe Others Market by Country
    • 4.2.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country
      • 4.2.2.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.1.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.2 UK Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.2.1 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.3 France Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.3.1 France Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.4 Russia Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.4.1 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.5 Spain Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.5.1 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.6 Italy Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.6.1 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.2.2.7 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.2.2.7.1 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
  • 4.3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market
    • 4.3.1 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.1.1 Asia Pacific C.difficile Market by Country
      • 4.3.1.2 Asia Pacific Crohns Disease Market by Country
      • 4.3.1.3 Asia Pacific IBS Market by Country
      • 4.3.1.4 Asia Pacific Diabetes Market by Country
      • 4.3.1.5 Asia Pacific Others Market by Country
    • 4.3.2 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country
      • 4.3.2.1 China Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.1.1 China Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.2 Japan Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.2.1 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.3 India Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.3.1 India Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.4 South Korea Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.4.1 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.5 Singapore Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.5.1 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.6 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.6.1 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.3.2.7 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.3.2.7.1 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
  • 4.4 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
    • 4.4.1 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.1.1 LAMEA C.difficile Market by Country
      • 4.4.1.2 LAMEA Crohns Disease Market by Country
      • 4.4.1.3 LAMEA IBS Market by Country
      • 4.4.1.4 LAMEA Diabetes Market by Country
      • 4.4.1.5 LAMEA Others Market by Country
    • 4.4.2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country
      • 4.4.2.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.1.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.2 Argentina Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.2.1 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.3 UAE Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.3.1 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.4 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.4.1 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.5 South Africa Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.5.1 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.6 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.6.1 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application
      • 4.4.2.7 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
        • 4.4.2.7.1 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application

Chapter 5. Company Profiles

  • 5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
    • 5.1.1 Company Overview
    • 5.1.2 Financial Analysis
    • 5.1.3 Segmental and Regional Analysis
    • 5.1.4 Recent strategies and developments:
      • 5.1.4.1 Acquisition and Mergers:
      • 5.1.4.2 Geographical Expansions:
  • 5.2 Cerbios-Pharma SA
    • 5.2.1 Company Overview
  • 5.3 Biose Industrie
    • 5.3.1 Company Overview
    • 5.3.2 Recent strategies and developments:
      • 5.3.2.1 Geographical Expansions:
  • 5.4 List Biological Laboratories, Inc.
    • 5.4.1 Company Overview
  • 5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
    • 5.5.1 Company Overview
  • 5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
    • 5.6.1 Company Overview
    • 5.6.2 Financial Analysis
    • 5.6.3 Segmental and Regional Analysis
    • 5.6.4 Research & Development Expenses
  • 5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
    • 5.7.1 Company Overview
    • 5.7.2 Financial Analysis
    • 5.7.3 Segmental Analysis
    • 5.7.4 Recent strategies and developments:
      • 5.7.4.1 Partnerships, Collaborations, and Agreements:
  • 5.8 BiomX, Inc.
    • 5.8.1 Company Overview
    • 5.8.2 Research & Development Expenses
  • 5.9 Lonza Group AG
    • 5.9.1 Company Overview
    • 5.9.2 Financial Analysis
    • 5.9.3 Segmental and Regional Analysis
    • 5.9.4 Research & Development Expenses
    • 5.9.5 Recent strategies and developments:
      • 5.9.5.1 Acquisition, Joint Ventures, and Mergers:
  • 5.10. 4D Pharma Plc
    • 5.10.1 Company Overview
    • 5.10.2 Financial Analysis
    • 5.10.3 Research & Development Expense